Heparan sulfate-dependent ERK activation contributes to the overexpression of fibrotic proteins and enhanced contraction by scleroderma fibroblasts

Arthritis and Rheumatism

Volumn 58, Issue 2, 2008, Pages 577-585

  Chen, Yunliang ^a   Leask, Andrew ^b   Abraham, David J ^a   Pala, Daphne ^b   Shiwen, Xu ^a   Khan, Korsa ^a   Liu, Shangxi ^b   Carter, David E ^c   Wilcox Adelman, Sarah ^d   Goetinck, Paul ^d   Denton, Christopher P ^a   Black, Carol M ^a   Pitsillides, Andrew A ^e   Sarraf, Catherine E ^f   Eastwood, Mark ^f  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b WESTERN UNIVERSITY   (Canada)

^c London Regional Genomics Centre   (Canada)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e ROYAL VETERINARY COLLEGE   (United Kingdom)

^f UNIVERSITY OF WESTMINSTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; ALPHA4 INTEGRIN; BETA1 INTEGRIN; CELL PROTEIN; HEPARAN SULFATE; HEPARIN; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; RAS PROTEIN; SYNDECAN 4;

ARTICLE; BIOLOGICAL MONITORING; CELL FUNCTION; CONTROLLED STUDY; ENZYME ACTIVATION; FIBROBLAST; FIBROGENESIS; FORCE; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCLERODERMA; SKIN DEFECT; SKIN FIBROBLAST; SYSTEMIC SCLEROSIS;

CELL MOVEMENT; CELLS, CULTURED; DERMIS; EXTRACELLULAR MATRIX; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; FIBROBLASTS; FIBROSIS; GENE EXPRESSION; HEPARAN SULFATE PROTEOGLYCANS; HEPARITIN SULFATE; HUMANS; MAP KINASE SIGNALING SYSTEM; PHENOTYPE; PLATELET-DERIVED GROWTH FACTOR; RNA, MESSENGER; SCLERODERMA, SYSTEMIC; SYNDECAN-4;

EID: 39749136487     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.23146     Document Type: Article

References (44)

1. Turck CW, Dohlman JG, Goetzl EJ. Immunological mediators of wound healing and fibrosis. J Cell Physiol Suppl 1987;Suppl 5:89-93.
2. Black CM. Scleroderma: clinical aspects. J Intern Med 1993;234:115-8.
3. Furst DE, Clements PJ. Hypothesis for the pathogenesis of systemic sclerosis. J Rheumatol Suppl 1997;48:53-7.
4. LeRoy C. Increased collagen synthesis by scleroderma skin fibroblasts in vitro: a possible defect in the regulation or activation of the scleroderma fibroblast. J Clin Invest 1974;54:880-9.
5. Shi-wen X, Pennington D, Holmes A, Leask A, Bradham D, Beauchamp JR, et al. Autocrine overexpression of CTGF maintains fibrosis: RDA analysis of fibrosis genes in systemic sclerosis. Exp Cell Res 2000;259:213-24.
6. Abraham DJ, Shiwen X, Black CM, Sa S, Xu Y, Leask A. Tumor necrosis factor α suppresses the induction of connective tissue growth factor by transforming growth factor-β in normal and scleroderma fibroblasts. J Biol Chem 2000;275:15220-5.
7. Desmouliere A, Gabbiani G. Myofibroblast differentiation during fibrosis. Exp Nephrol 1995;3:134-9.
8. Jimenez SA, Hitraya E, Varga J. Pathogenesis of scleroderma: collagen. Rheum Dis Clin North Am 1996;22:647-74.
9. Shi-wen X, Chen Y, Denton CP, Eastwood M, Renzoni E, Bou-Gharios G, et al. Endothelin-1 promotes mechanoregulation and myofibroblast formation in fibroblasts through the ETA receptor via Akt/PI3 kinase: implications for lung fibrosis. Mol Biol Cell 2004;15:2707-19.
10. Chen Y, Shi-wen X, van Beek J, Kennedy L, McLeod M, Renzoni EA, et al. Matrix contraction by dermal fibroblasts requires transforming growth factor-β/activin-linked kinase 5, heparan sulfate-containing proteoglycans, and MEK/ERK: insights into pathological scarring in chronic fibrotic disease. Am J Pathol 2005;167:1699-711.
11. Bernfield M, Gotte M, Park PW, Reizes O, Fitzgerald ML, Lincecum J, et al. Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem 1999;68:729-77.
12. Tumova S, Woods A, Couchman JR. Heparan sulfate proteoglycans on the cell surface: versatile coordinators of cellular functions. Int J Biochem Cell Biol 2000;32:269-88.
13. Stratton R, Rajkumar V, Ponticos M, Nichols B, Shiwen X, Black CM, et al. Prostacyclin derivatives prevent the fibrotic response to TGF-β by inhibiting the Ras/MEK/ERK pathway. FASEB J 2002;16:1949-51.
14. Leask A, Holmes A, Black CM, Abraham DJ. CTGF gene regulation: requirements for its induction by TGFβ in fibroblasts. J Biol Chem 2003;278:13008-15.
15. Chen Y, Blom IE, Sa S, Goldschmeding R, Abraham DJ, Leask A. CTGF expression in mesangial cells: involvement of SMADs, MAP kinase, and PKC. Kidney lnt 2002;62:1149-59.
16. Stratton R, Shiwen X, Martini G, Holmes A, Leask A, Haberberger T, et al. Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients. J Clin Invest 2001;108:241-50.
17. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic scleras is (scleroderma). Arthritis Rheum 1980;23:581-90.
18. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5.
19. Chen Y, Abraham DJ, Shi-wen X, Pearson JD, Black CM, Lyons KM, et al. CCN2 (connective tissue growth factor) promotes fibroblast adhesion to fibronectin. Mol Biol Cell 2004;15:5635-40.
20. Carey DJ, Rafferty CM, Todd MS. Effects of inhibition of proteoglycan synthesis on the differentiation of cultured rat Schwann cells. J Cell Biol 1987;105:1013-21.
21. Hamati HF, Britton EL, Carey DJ. Inhibition of proteoglycan synthesis alters extracellular matrix deposition, proliferation, and cytoskeletal organization of rat aortic smooth muscle cells in culture. J Cell Biol 1989;108:2495-505.
22. Haggerty JG, Bretton RH, Milstone LM. Response of stratified cultures of human keratinocytes to disruption of proteoglycan synthesis by p-nitrophenyl-β-D-xylopyranoside. J Cell Physiol 1994;158:39-46.
23. Shi-wen X, Stanton LA, Kennedy L, PaIa D, Chen Y, Howat SL, et al. CCN2 is necessary for adhesive responses to transforming growth factor-β1 in embryonic fibroblasts. J Biol Chem 2006;281:10715-26.
24. Eastwood M, Porter R, Khan U, McGrouther G, Brown R. Quantitative analysis of collagen gel contractile forces generated by dermal fibroblasts and the relationship to cell morphology. J Cell Physiol 1996;166:33-42.
25. Tomasek JJ, Gabbiani G, Hinz B, Brown RA. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol 2002;3:349-63.
26. Eastwood M, McGrouther G, Brown RA. A culture force monitor for measurement of contraction forces generated in human dermal fibroblast cultures: evidence for cell-matrix mechanical signalling. Biochim Biophys Acta 1994;1201:186-92.
27. Midwood KS, Valenick LV, Hsia HC, Schwarzbauer JE. Coregulation of fibronectin signaling and matrix contraction by tenascin-C and syndecan-4. Mol Biol Cell 2004;15:5670-7.
28. Greene DK, Tumova S, Couchman JR, Woods A. Syndecan-4 associates with α-actinin. J Biol Chem 2003;278:7617-23.
29. Tolic-Norrelykke IM, Wang N. Traction in smooth muscle cells varies with cell spreading. J Biomech 2005;38:1405-12.
30. Grinnell F. Fibroblast biology in three-dimensional collagen matrices. Trends Cell Biol 2003;13:264-9.
31. Lin F, Ren XD, Doris G, Clark RA. Three-dimensional migration of human adult dermal fibroblasts from collagen lattices into fibrin/fibronectin gels requires syndecan-4 proteoglycan. J Invest Dermatol 2005;124:906-13.
32. Baroni SS, Santillo M, Bevilacqua F, Luchetti M, Spadoni T, Mancini M, et al. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 2006;354:2667-76.
33. Chen Y, Shi-wen X, Eastwood M, Black CM, Denton CP, Leask A, et al. Contribution of activin receptor-like kinase 5 (transforming growth factor βreceptor type I) signaling to the fibrotic phenotype of scleroderma fibroblasts. Arthritis Rheum 2006;54:1309-16.
34. Shi-Wen X, Rodriguez-Pascual F, Lamas S, Holmes A, Howat S, Pearson JD, et al. Constitutive ALK5-independent c-Jun N-terminal kinase activation contributes to endothelin-1 overexpression in pulmonary fibrosis: evidence of an autocrine endothelin loop operating through the endothelin A and B receptors. Mol Cell Biol 2006;26:5518-27.
35. McGrath JA, Eady RA. Heparan sulphate proteoglycan and wound healing in skin. J Pathol 1997;183:251-2.
36. Rabenstein DL. Heparin and heparan sulfate: structure and function. Nat Prod Rep 2002;19:312-31.
37. Tourkina E, Gooz P, Pannu J, Bonner M, Scholz D, Hacker S, et al. Opposing effects of protein kinase Ca and protein kinase Cε on collagen expression by human lung fibroblasts are mediated via MEK/ERK and caveolin-1 signaling. J Biol Chem 2005;280:13879-87.
38. Leask A, Abraham DJ, Finlay DR, Holmes A, Pennington D, Shi-Wen X, et al. Dysregulation of transforming growth factor β signaling in scleroderma: overexpression of endoglin in cutaneous scleroderma fibroblasts. Arthritis Rheum 2002;46:1857-65.
39. Pannu J, Gore-Hyer E, Yamanaka M, Smith EA, Rubinchik S, Dong JY, et al. An increased transforming growth factor β receptor type I: type II ratio contributes to elevated collagen protein synthesis that is resistant to inhibition via a kinase-deficient transforming growth factor β receptor type II in scleroderma. Arthritis Rheum 2004;50:1566-77.
40. Bonniaud P, Margetts PJ, Kolb M, Schroeder JA, Kapoun AM, Damm D, et al. Progressive transforming growth factor β1-induced lung fibrosis is blocked by an orally active ALK5 kinase inhibitor. Am J Respir Crit Care Med 2005;171:889-98.
41. Leask A, Abraham DJ. TGF-β signaling and the fibrotic response. FASEB J 2004;18:816-27.
42. Shi-wen X, Howat SL, Renzoni EA, Holmes A, Pearson JD, Dashwood MR, et al. Endothelin-1 induces expression of matrix-associated genes in lung fibroblasts through MEK/ERK. J Biol Chem 2004;279:23098-103.
43. Sethi KK, Yannas IV, Mudera V, Eastwood M, McFarland C, Brown RA. Evidence for sequential utilization of fibronectin, vitronectin, and collagen during fibroblast-mediated collagen contraction. Wound Repair Regen 2002;10:397-408.
44. Leask A. Scar wars: is TGFβ the phantom menace in scleroderma? [review]. Arthritis Res Ther 2006;8:213.